GLP-1 Digest

GLP-1 Digest

Home
Podcast
Archive
Leaderboard
About
India is not the opportunity you think it is
Why DTC telehealth won't work in India's GLP-1 market
Mar 26 • Ashwin Sharma, MD
🎧 Should GLP-1s be sold over the counter? Ep 3, with Dr. Beverly Tchang, MD
On the maintenance trap, microdosing for prevention, and frictionless access
Mar 8 • Ashwin Sharma, MD
1:19:22
🎧 What investors get wrong about Hims & Hers, Ep. 2 with Paul Cerro
Listen now | The definitive Q4 2025 earnings breakdown
Mar 1 • Ashwin Sharma, MD
1:09:46
🎧 The GLP-1 business model problem, Ep. 1 with Prof. Alex Miras
Why the drug does the heavy lifting, price trumps everything, and muscle loss might not be what we think
Feb 15 • Ashwin Sharma, MD
1:09:43
GLP-1s go to the Super Bowl
Ro bets big, Novo's oral Wegovy finally arrives, and Hims crosses a line with the FDA
Feb 8 • Ashwin Sharma, MD
Consumer health apps are dead
Long live the agents
Jan 11 • Ashwin Sharma, MD
The 5 most important ideas for 2026
Seismic shifts are underway in the GLP-1 market
Dec 29, 2025 • Ashwin Sharma, MD
Is Your Telehealth Platform Scaring Patients Away?
Design is the overlooked moat in digital health
Dec 16, 2025 • Ashwin Sharma, MD
GLP-1 Digest
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Recommendations
Big Pharma Sharma
Big Pharma Sharma
Big Pharma Sharma
The Argument
The Argument
Jerusalem Demsas
The Gut Group
The Gut Group
Dr Arif Hussenbux MBBS
The Device Files: From Concept to Commercialization
The Device Files: From Concept to Commercialization
Blythe Karow
In-Network
In-Network
David Ohta

GLP-1 Digest

AboutArchiveRecommendationsSitemap
© 2026 Ashwin Sharma · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture